Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Rabies | 1 | 2017 | 113 | 0.60 | Why? |
| Epstein-Barr Virus Infections | 1 | 2017 | 366 | 0.50 | Why? |
| Whole Genome Sequencing | 2 | 2021 | 3239 | 0.49 | Why? |
| Cytomegalovirus Infections | 1 | 2017 | 667 | 0.43 | Why? |
| Travel-Related Illness | 1 | 2017 | 1357 | 0.40 | Why? |
| London | 6 | 2021 | 2166 | 0.36 | Why? |
| Genome, Viral | 3 | 2021 | 13157 | 0.33 | Why? |
| Influenza A virus | 1 | 2018 | 2234 | 0.31 | Why? |
| Cross Infection | 3 | 2021 | 8675 | 0.24 | Why? |
| Heme | 1 | 2021 | 110 | 0.21 | Why? |
| Fever | 1 | 2017 | 7795 | 0.21 | Why? |
| Medical Laboratory Science | 1 | 2020 | 122 | 0.19 | Why? |
| Disease Transmission, Infectious | 2 | 2018 | 9044 | 0.17 | Why? |
| Influenza, Human | 2 | 2018 | 10779 | 0.16 | Why? |
| Hemagglutinins | 1 | 2017 | 143 | 0.15 | Why? |
| Molecular Epidemiology | 2 | 2018 | 1638 | 0.15 | Why? |
| Residential Facilities | 1 | 2020 | 443 | 0.15 | Why? |
| Infection Control | 3 | 2020 | 23131 | 0.14 | Why? |
| Polymerase Chain Reaction | 2 | 2021 | 6740 | 0.13 | Why? |
| Viral Load | 3 | 2021 | 15850 | 0.13 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.13 | Why? |
| Phylogeny | 5 | 2021 | 13341 | 0.13 | Why? |
| Sex Characteristics | 1 | 2021 | 1120 | 0.12 | Why? |
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2017 | 511 | 0.12 | Why? |
| HIV-1 | 2 | 2018 | 3365 | 0.12 | Why? |
| Influenza A Virus, H3N2 Subtype | 1 | 2017 | 572 | 0.12 | Why? |
| Multiple Myeloma | 1 | 2021 | 1064 | 0.11 | Why? |
| HIV Infections | 4 | 2018 | 11620 | 0.11 | Why? |
| Molecular Sequence Data | 2 | 2017 | 3198 | 0.11 | Why? |
| DNA, Complementary | 1 | 2013 | 568 | 0.11 | Why? |
| Diagnostic Errors | 1 | 2017 | 865 | 0.10 | Why? |
| RNA, Viral | 3 | 2018 | 32276 | 0.10 | Why? |
| Qatar | 1 | 2013 | 784 | 0.10 | Why? |
| Jordan | 1 | 2013 | 701 | 0.10 | Why? |
| Seroconversion | 1 | 2020 | 2515 | 0.10 | Why? |
| HIV | 1 | 2017 | 1116 | 0.10 | Why? |
| Inflammation Mediators | 1 | 2021 | 2654 | 0.10 | Why? |
| Long-Term Care | 1 | 2020 | 2047 | 0.09 | Why? |
| United Kingdom | 4 | 2021 | 18046 | 0.09 | Why? |
| DNA Primers | 1 | 2013 | 1170 | 0.09 | Why? |
| Epilepsy | 1 | 2020 | 1401 | 0.09 | Why? |
| Guideline Adherence | 1 | 2021 | 2309 | 0.09 | Why? |
| Immunity, Cellular | 1 | 2021 | 3614 | 0.09 | Why? |
| Spike Glycoprotein, Coronavirus | 4 | 2021 | 37182 | 0.08 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.08 | Why? |
| Smartphone | 1 | 2017 | 1840 | 0.08 | Why? |
| Immunity, Humoral | 1 | 2020 | 4849 | 0.08 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 3633 | 0.07 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.07 | Why? |
| Base Sequence | 1 | 2013 | 3581 | 0.07 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.07 | Why? |
| Zika Virus Infection | 1 | 2018 | 1920 | 0.07 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.07 | Why? |
| Humans | 26 | 2021 | 930598 | 0.07 | Why? |
| Point-of-Care Systems | 1 | 2017 | 2955 | 0.07 | Why? |
| Coronavirus | 1 | 2013 | 18339 | 0.07 | Why? |
| Biosensing Techniques | 1 | 2017 | 2116 | 0.06 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.06 | Why? |
| Communicable Diseases, Emerging | 1 | 2017 | 2523 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Patient Acceptance of Health Care | 1 | 2021 | 5002 | 0.06 | Why? |
| Saudi Arabia | 1 | 2013 | 4423 | 0.06 | Why? |
| Biliverdine | 1 | 2021 | 50 | 0.06 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.06 | Why? |
| Female | 13 | 2021 | 380317 | 0.05 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2018 | 5164 | 0.05 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.05 | Why? |
| Cluster Analysis | 2 | 2018 | 3001 | 0.05 | Why? |
| Middle Aged | 8 | 2021 | 270681 | 0.05 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.05 | Why? |
| Wales | 1 | 2021 | 758 | 0.04 | Why? |
| Sequence Analysis, DNA | 2 | 2017 | 2830 | 0.04 | Why? |
| Bilirubin | 1 | 2021 | 503 | 0.04 | Why? |
| Chiroptera | 1 | 2013 | 3530 | 0.04 | Why? |
| Point Mutation | 1 | 2021 | 481 | 0.04 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 13720 | 0.04 | Why? |
| Ukraine | 1 | 2017 | 137 | 0.04 | Why? |
| Antibody Formation | 2 | 2021 | 4038 | 0.04 | Why? |
| Genetic Drift | 1 | 2017 | 54 | 0.04 | Why? |
| Male | 11 | 2021 | 367725 | 0.04 | Why? |
| HEK293 Cells | 2 | 2021 | 8394 | 0.04 | Why? |
| Academies and Institutes | 1 | 2020 | 539 | 0.04 | Why? |
| Immune Sera | 1 | 2021 | 884 | 0.04 | Why? |
| Heterosexuality | 1 | 2017 | 148 | 0.04 | Why? |
| Epidemics | 1 | 2017 | 6407 | 0.04 | Why? |
| Disease Outbreaks | 3 | 2021 | 27595 | 0.04 | Why? |
| Calibration | 1 | 2017 | 307 | 0.04 | Why? |
| Microcephaly | 1 | 2018 | 181 | 0.04 | Why? |
| Epitope Mapping | 1 | 2020 | 1240 | 0.04 | Why? |
| Aged | 6 | 2021 | 215776 | 0.04 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.04 | Why? |
| Time | 1 | 2017 | 631 | 0.04 | Why? |
| Crystallography, X-Ray | 1 | 2021 | 2689 | 0.03 | Why? |
| Interleukin-10 | 1 | 2020 | 1409 | 0.03 | Why? |
| Cryoelectron Microscopy | 1 | 2021 | 2372 | 0.03 | Why? |
| Substance Abuse, Intravenous | 1 | 2018 | 411 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Adult | 9 | 2021 | 244371 | 0.03 | Why? |
| Hospitals, Teaching | 1 | 2021 | 1609 | 0.03 | Why? |
| Glycosylation | 1 | 2017 | 1255 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.03 | Why? |
| L-Lactate Dehydrogenase | 1 | 2020 | 1995 | 0.03 | Why? |
| Immunomodulation | 1 | 2021 | 1472 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2018 | 11559 | 0.03 | Why? |
| Antibodies, Monoclonal | 2 | 2021 | 8041 | 0.03 | Why? |
| Animals | 3 | 2020 | 78931 | 0.03 | Why? |
| Bayes Theorem | 1 | 2021 | 3237 | 0.03 | Why? |
| South Africa | 1 | 2021 | 3326 | 0.03 | Why? |
| Greece | 1 | 2018 | 2091 | 0.03 | Why? |
| Recombination, Genetic | 1 | 2018 | 1265 | 0.03 | Why? |
| Drug Resistance, Viral | 1 | 2017 | 1083 | 0.03 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.03 | Why? |
| Amino Acid Substitution | 1 | 2017 | 1706 | 0.02 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.02 | Why? |
| England | 1 | 2021 | 5116 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2020 | 6049 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.02 | Why? |
| Epitopes | 1 | 2021 | 4113 | 0.02 | Why? |
| Homosexuality, Male | 1 | 2017 | 1158 | 0.02 | Why? |
| State Medicine | 1 | 2021 | 2847 | 0.02 | Why? |
| Sexual and Gender Minorities | 1 | 2017 | 1019 | 0.02 | Why? |
| Parents | 1 | 2021 | 2758 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.02 | Why? |
| Infant, Newborn | 2 | 2018 | 23105 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Young Adult | 3 | 2020 | 93724 | 0.02 | Why? |
| Receptors, Virus | 1 | 2021 | 5659 | 0.02 | Why? |
| Europe | 1 | 2020 | 12702 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Genetic Variation | 1 | 2017 | 3919 | 0.02 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2021 | 10649 | 0.01 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.01 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.01 | Why? |
| Contact Tracing | 1 | 2018 | 8448 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.01 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Viral Vaccines | 1 | 2018 | 7560 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.01 | Why? |
| Child | 1 | 2017 | 70012 | 0.01 | Why? |
| Adolescent | 1 | 2017 | 86841 | 0.00 | Why? |
| Pandemics | 1 | 2020 | 389249 | 0.00 | Why? |
Nastouli's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(158)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(337)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_